Using the Oncogramme® Device to Choose Treatment for Metastatic Colorectal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of the Oncogramme® device in selecting the first line of treatment for patients diagnosed with metastatic colorectal cancer (mCRC). The study aims to improve treatment decisions by utilizing personalized data from the Oncogramme® to guide chemotherapy choices, which may include various combinations of drugs. Eligible participants will be those with confirmed colorectal adenocarcinoma and measurable metastases, who are set to receive standard systemic chemotherapy. The trial will compare outcomes based on treatment decisions made with and without the Oncogramme® results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years old and older
* Patient with suspected mCRC (synchronous or metachronous metastases (only if biopsy is required as part of routine care))
* Patient eligible for standard systemic chemotherapy (multidrug therapy such as FOLFOX, FOLFIRI, FOLFIRINOX, combined or not with anti- EGFR or anti-VEGF targeted therapies adapted to BRAF and RAS expression)
* colorectal adenocarcinoma histologically proven
* At least one measurable metastasis according to RECIST v1.1
* Chemotherapy for curative or palliative purposes
* Oncograms® can be performed
* WHO score ≤ 2
* Life expectancy \> 3 months
* neutrophils \> 1500/mm3, platelets \> 100 000/mm3, Hb \> 9 g/dL
* Total bilirubin \< 25 μmol/L, aspartate aminotransferase \< 5 ULN (upper limits of normal), alanine aminotransferase \< 5 ULN, alkaline phosphatase \< 5 ULN, prothrombin rate \> 60%, proteinuria \< 1 g/24h
* No prior chemotherapy except peri-operative or adjuvant chemotherapy stopped more than 6 months ago
* Creatinine clearance \> 50 mL/min according to MDRD formula
* Patient affiliated to a social security scheme
* Information to the patient and signature of the informed consent form.

Exclusion Criteria:

* Patients eligible for curative treatment (surgical and/or percutaneous) after discussion in multidisciplinary consultation meeting (isolated class I liver metastases)
* Patients with metachronous metastases not requiring biopsy as part of their standard management.
* Myocardial infarction, severe/unstable angina, coronary artery bypass grafting, New York Heart Association (NYHA) class II, III, or IV congestive heart failure, stroke, or transient ischemic attack within 6 months prior to inclusion
* HTA not controlled by medical treatment (systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg)
* History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding in the 6 months preceding the start of treatment
* Active peptic ulcer
* Deep wound or bone fracture not resolved within 3 months
* Major abdominal or extra-abdominal surgical procedure (except diagnostic biopsy or implantable site placement)
* Irradiation within 4 weeks prior to the start of treatment
* Transplant patients, HIV-positive, or other immunodeficiency syndromes
* Previous chemotherapy (except peri-operative or adjuvant chemotherapy discontinued more than 6 months ago)
* Any progressive disease not balanced during the last 6 months: hepatic insufficiency, renal insufficiency, respiratory insufficiency
* Peripheral neuropathy \> 1 (CTCAE Common terminology criteria for adverse eventsv5.0)
* Patient with interstitial lung disease or pulmonary fibrosis
* History of chronic diarrhea or inflammatory disease of the colon or rectum, or occlusion or sub-occlusion unresolved with symptomatic treatment
* History of malignancy within the last 5 years except for properly treated non-metastatic colon cancer, basal cell skin carcinoma or carcinoma in situ of the uterine cervix
* Patient already included in another therapeutic trial with an investigational treatment or who has been out of a trial for less than 6 months
* Any specific contraindication or known allergy to the drugs used in the study.
* Known dihydropyrimidine dehydrogenase deficiency
* QT/QTc interval \> 450 ms for men and \> 470 ms for women
* Kalemia (K+) \< LIN (lower limit to normal), magnesemia (Mg2+)\< LIN, calcemia (Ca2+)\< LIN
* Lack of effective contraception (at least 2 different means) in patients (male or/and female) of childbearing age, or for females, 12 months of confirmed amenorrhea, pregnant or lactating woman, woman of childbearing age who has not performed a pregnancy test (serum test)
* Persons deprived of liberty or under guardianship
* Impossible to undergo the medical follow-up of the trial for geographical, social or psychological reasons.

Where it's running

• Hôpital Saint Joseph Marseille
  Marseille, France Recruiting

Study contacts

• Principal investigator: Hervé Perrier, M.D — Hopital Saint Joseph Marseille
• Study coordinator: Christophe Lautrette, PhD
• Email: c.lautrette@oncomedics.com
• Phone: 0033 5 55 33 85 25

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Immunotherapy plus Simvastatin and Targeted Therapy with Chemotherapy for Advanced Colorectal Cancer

  This trial tests whether adding immune therapy (adbelimumab? actually Adebrelimab) with simvastatin and targeted therapy to standard chemotherapy helps people with metastatic colorectal cancer that is MSI-H/dMMR or MSS/pMMR depending on combination.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 1 other locations · NCT07718490

• Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

  This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.

  Recruiting at 3 sites Takeda · Poznan, Greater Poland Voivodeship and 9 other locations · NCT07623174

• Understanding why BRAF V600E colorectal cancer stops responding to targeted therapy

  This study tests why metastatic colorectal cancer with a BRAF V600E mutation stops responding to encorafenib and cetuximab, by collecting tissue, blood, and stool samples over time.

  Recruiting at 13 sites Swiss Cancer Institute · Aarau and 12 other locations · NCT07617610

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.